Immunic Restores Nasdaq Listing by Meeting $1.00 Bid Price for 20 Days
Immunic regained compliance with Nasdaq Rule 5550(a)(2) from March 26, 2026 after its common stock closed at $1.00 or higher for 20 consecutive business days. The Nasdaq Listing Qualifications Department closed the matter on March 27, ending the minimum bid price deficiency.
1. Nasdaq Compliance Regained
Immunic regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after its stock closed at $1.00 or greater for 20 consecutive business days, satisfying the rule as of March 26, 2026.
2. Listing Qualifications Closed Matter
The Nasdaq Listing Qualifications Department issued written notice on March 27, 2026 confirming the company’s continued listing status and closing the deficiency matter with no further action required.
3. Clinical Pipeline Status
Immunic’s lead candidate, vidofludimus calcium (IMU-838), is in Phase 3 trials for relapsing multiple sclerosis with top-line data expected by end of 2026, while earlier-stage programs IMU-856 and IMU-381 advance the company’s neurotherapeutics pipeline.